REG - BSF Enterprise PLC - Admittance to trading on the OTCQB Venture Market

BSF EnterpriseAnnouncement

25/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230525:nRSY5663Aa&default-theme=true

RNS Number : 5663A  BSF Enterprise PLC  25 May 2023

25 May 2023

 

BSF Enterprise PLC

("BSF" or the "Company")

 

Admittance to trading on the OTCQB Venture Market

 

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and
the owner of pioneering UK-based clinical and cellular agriculture company 3D
Bio-Tissues, is pleased to announce that the Company's Ordinary Shares
("Ordinary Shares") were admitted to trading on the OTCQB Venture Market in
the United States on 24 May 2023.  The shares trade under the symbol BSFAF.

 

Trading on the OTCQB market provides BSF with access to one of the world's
largest investment markets, expanding the Company's reach to a broader pool of
investors while creating the potential for greater liquidity in its shares.
Shares will also be available to US investors during US trading hours, priced
in US dollars. This will ease cross-border trading, with the potential to
further enhance liquidity.

 

There is no capital raise associated with BSF trading on the OTCQB market and
BSF's Ordinary Shares will continue to trade on its primary listing, the Main
Market of the London Stock Exchange, under the ticker BSFA.

 

Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues,
commented: "We are delighted to have joined the OTCQB market. This is an
important step for BSF which provides access to a wider investor audience from
which to raise funds and improve liquidity. In addition, it will help to raise
our profile in the US and beyond, a timely development given that we are in
the process of establishing sales channels across key global markets including
the US. This was demonstrated in our announcement released earlier this week,
detailing the headway we are already making in delivering new contracts and
distribution partners. Together, these developments give us confidence in our
ability to drive additional momentum in the coming months."

 

Further Information on BSF's application and the OTCQB market below:

 

As a Foreign Private Issuer, BSF's onboarding to the OTC Markets is based on
satisfaction of the requirements for OTCQB as applicable to international
reporting companies including satisfaction of the criteria for the exemption
under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule
12g3-2(b) exemption includes the disclosure obligation to ensure that certain
information made public or distributed under home market regulations is made
publicly available on the Company's website or other electronic information
delivery system in English. Thus, the Company will have no additional
reporting obligations and incur minimal ongoing costs, compared to traditional
major exchanges.

 

As a verified market, the OTCQB offers transparent trading for companies that
have met a minimum bid price test, are current in their financial reporting
and have undergone an annual verification and management certification
process. The cross-trading facility is provided through OTC Markets Group
Inc., located in New York. OTC Markets operates the world's largest electronic
interdealer quotation system for US broker dealers and offers multiple media
channels to increase the visibility of OTC-listed companies. Online brokers
such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and
E-trade all offer OTCQB trades. US investors can find real-time quotes, market
information and access current company news and developments on a BSF page on
the OTC Markets website after the application is completed .

 

BSF has appointed B. Riley Financial Company as its OTCQB Sponsor and is
advised by Ince & Co Lawyers in London.

 

Additional information about the OTCQB market can be found at:

www.otcmarkets.com/learn/market-101
(http://www.otcmarkets.com/learn/market-101)

 

 

-Ends-

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                         Via SEC Newgate below
 Che Connon - CEO & Executive Director

 Geoff Baker - Executive Director

 Shard Capital (Broker)
 Damon Heath                                0203 971 7000

 SEC Newgate (Financial Communications)
 Bob Huxford                                020 3757 6882

 Elisabeth Cowell                           BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
acquiring complementary businesses. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas, meat and
leather, and license out the IP to manufacturers, wholesalers and distributors
to help manufacture the products at scale.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUBWAUPWGQC